The membranes were incubated with a primary monoclonal antibody to PKC[beta]I (E-3: sc-8049; 1:1000; Santa Cruz Biotechnology, Dallas, CA, USA) , PKQ3II (Y125: ab32026; 1: 1000; Abcam, Cambridge, UK) , NHE1 (54: sc-136239; 1:500; Santa Cruz Biotechnology) , NHE3
(19F5: sc-58636; 1:1000; Santa Cruz Biotechnology) , or [beta]-actin (Santa Cruz Biotechnology), followed by the respective horseradish peroxidase-linked secondary antibody (Bio-Rad).
While both osteoblasts (cathode-directed) and osteosarcoma (anode-directed) cells express similar channels such as NHE3
, NHE1, and Na, K-ATPase (NaKA), they are differentially activated in the presence of EFs and their inhibition has different effects on their migratory behaviour .
Proximal tubule [Na.sup.+] transport is thus primarily driven by NKA and predominantly accomplished by NHE3
on the apical membrane and NBCe1 on the basolateral membrane (Figure 1).
Ardelyx formed a partnership with AstraZeneca in October 2012 to develop and commercialize Ardelyx's internally discovered portfolio of NHE3
inhibitors including tenapanor.
Abnormalities in the transporters involved in acid-base regulation were also observed, including an increased expression of NHE3
(proximal tubule), H-ATPase and pendrin (distal tubule) in patients with ACL, which could explain the urinary acidification deficit.
Peptide ligands of the extracellular domain of GC-C activate the intracellular catalytic domain of GC-C resulting in cGMP formation, which activates several pathways: a) inhibition of the NHE3
transporter, which decreases NaCl absorption; b) activation of CFTR, which leads to secretion of chloride; and c) increased calcium influx.
We found that CR upregulated sodium-hydrogen exchanger 3 (NHE3
) expression in the kidney (Figure 3(b)).
Kim, "Altered expression of Reanl AQP1, AQP2 and NHE3
puromycin aminonucleoside induced nephrotic syndrome: intervention by alpha-MSH treatment," Korean Journal of Nephrology, vol.
We have previously demonstrated that epidermal growth factor (EGF) and high-glucose induced sodium reabsorption in proximal tubule cells by increasing the activity of the sodium hydrogen exchanger-3 (NHE3
AstraZeneca and Ardelyx today announced a worldwide exclusive licensing agreement for Ardelyx s NHE3
inhibitor programme, including the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Albumin endocytosis requires a macromolecular protein complex formed by the megalin/cubilin scavenger receptor [Na.sup.+]-[H.sup.+] exchanger isoform 3 (NHE3
), vacuolar proton-ATPase (v-[H.sup.+]-ATPase), and chloride channel 5 (ClC5).
The target genes tested in the present study were the epithelia ion producer, carbonic anhydrase II (CAII), and the ion transporters, [Na.sup.+]/[H.sup.+] exchanger 3 (NHE3
), a [Cl.sup.-]/HC[O.sub.3.sup.-] exchanger, down-regulated in adenoma (DRA), cystic fibrosis transmembrane regulator (CFTR), and [Na.sup.+]/[K.sup.+] ATPase (ATPase) [alpha]1 subunit.